Table 6.
Parameter | Groups | 2-Year LRFS(%) | 5-Year LRFS(%) | 10-Year LRFS(%) | χ2 Test-Value | p-value |
---|---|---|---|---|---|---|
Age | 19–49 | 90 | 90 | 77 | 6.963 | 0.073 |
50–61 | 85 | 85 | 28 | |||
62–70 | 73 | 55 | 37 | |||
71–88 | 73 | 49 | 49 | |||
Gender | Female | 80 | 67 | 58 | 0.870 | 0.384 |
Male | 82 | 79 | 55 | |||
WHO | 0 | 96 | 96 | 85 | 19.689 | 0.002 |
1 | 74 | 63 | 43 | |||
2 | 58 | 19 | 0 | |||
3 | 0 | 0 | 0 | |||
Location | Parotid | 81 | 73 | 41 | 0.616 | 0.538 |
Submandibular | 81 | 74 | 62 | |||
Clinical nerve palsy | Yes | 74 | 67 | 33 | 1.610 | 0.107 |
No | 84 | 75 | 61 | |||
Radicality | R0 | 84 | 73 | 55 | 0.662 | 0.718 |
R1 | 82 | 73 | 58 | |||
R2 | 68 | 68 | 34 | |||
Nerve palsy after surgery | Yes | 83 | 74 | 58 | 1.081 | 0.279 |
No | 76 | 69 | 42 | |||
Histopathological type | Squamous | 61 | 51 | 0 | 11.104 | 0.049 |
Adenocarcinoma | 83 | 66 | 33 | |||
Cystic adenoid carcinoma | 95 | 95 | 95 | |||
Undifferentiated | 64 | 64 | 43 | |||
Acinic | 91 | 73 | 55 | |||
Other | 88 | 81 | 81 | |||
Neuroinvasion | Yes | 82 | 73 | 64 | 0.924 | 0.355 |
No | 79 | 74 | 39 | |||
Angioinvasion | Yes | 77 | 66 | 66 | 0.756 | 0.449 |
No | 82 | 74 | 52 | |||
Stage | I | 100 | 100 | 100 | 10.256 | 0.017 |
II | 87 | 77 | 58 | |||
III | 79 | 73 | 43 | |||
IVab | 70 | 59 | 39 | |||
T | 1 | 95 | 95 | 95 | 12.233 | 0.007 |
2 | 89 | 77 | 66 | |||
3 | 73 | 59 | 35 | |||
4 | 72 | 60 | 0 | |||
N | Positive | 69 | 61 | 40 | 1.684 | 0.092 |
Negative | 86 | 78 | 59 | |||
Time | <9 weeks | 83 | 78 | 71 | 1.247 | 0.213 |
≥9 weeks | 79 | 66 | 34 | |||
Technique of RT | 2D | 53 | 35 | 35 | 7.141 | 0.028 |
3D | 89 | 89 | 59 | |||
IMRT | 85 | 74 | 56 | |||
Dose | <60Gy | 64 | 52 | 26 | 2.653 | 0.008 |
≥60Gy | 86 | 78 | 60 | |||
CHT | Yes | 66 | 57 | 57 | 1.202 | 0.229 |
No | 84 | 76 | 54 | |||
Hemoglobin level | <12.5 mg/dL | 67 | 67 | N/A | 0.021 | 0.983 |
≥12.5 mg/dL | 75 | 59 | N/A | |||
Tumor volume | ≤10 cm3 | 95 | 95 | 95 | 5.129 | 0.162 |
10.1–50 cm3 | 86 | 74 | N/A | |||
50.1–100 cm3 | 81 | 73 | 0 | |||
>100 cm3 | 78 | 78 | N/A | |||
Irradiation area | Only surgical bed with margin | 91 | 76 | 61 | 5.129 | 0.163 |
Surgical bed + lnd.group I-II | 88 | 78 | N/A | |||
Surgical bed + unilateral lnd. | 81 | 77 | 5 | |||
Surgical bed + bilateral lnd | 61 | 61 | 61 | |||
Tumor bed volume (dose ≥ 60Gy) | ≤ 100cm3 | 94 | 94 | 94 | 5.543 | 0.136 |
100.1–200 cm3 | 83 | 83 | N/A | |||
200.1–300 cm3 | 73 | 64 | N/A | |||
>300 cm3 | 77 | 77 | 0 | |||
Elective area volume (dose ≥ 50Gy) | ≤150 cm3 | 94 | 88 | 63 | 8.759 | 0.067 |
150.1–300 cm3 | 80 | 70 | N/A | |||
300.1–450 cm3 | 75 | N/A | N/A | |||
450.1–600 cm3 | 58 | 58 | 0 | |||
>600 cm3 | 100 | 100 | N/A |
Note: Statistically significant results in bold.
Abbreviations: p, significance level; R0, radical surgery; R1, non-radical microscopic surgery; R2, non-radical macroscopic surgery; RT, radiotherapy; CHT, chemotherapy; RT, radiotherapy; 2D, two-dimensional planning; 3D, three-dimensional planning; IMRT, planning with intensity-modulated radiation therapy.